Skip to main content

Table 3 Studies reporting CD112 as a diagnostic and prognostic biomarker

From: The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

Reference First Author Year Type of cancer Sample size comments
[68] Miao et al. 2013 Gallbladder cancer 46 SC/ASCa
80 ACb
CD112 expression was associated with aggressiveness and poor prognosis
[44, 73] Daniel et al.
Huang et al.
2021
2014
Liver cancer 159 Low CD112 expression was associated with poor OS of patients, but contradicted by evidence from preclinical studies
[80] Karabulut et al. 2015 Colorectal carcinoma (CRC) 140 Serum CD112 levels have a diagnostic value and high levels correlated with an adverse prognostic impact on PFS patients with early-stage
[83] Liang et al. 2015 Pancreatic Ductal Adenocarcinomas 106 CD112 expression was associated with the progression and poor prognosis
[84] Izumi et al. 2015 Pancreatic adenocarcinoma 49 CD112 was not associated with overall survival, but higher CD112 expression correlated with worse histological grade.
[77] Stamm et al. 2018 AML 429c High CD112 expression correlated with shorter overall survival
[76] Erturk et al. 2019 Lung cancer 74 Serum CD112 expression level was a reliable diagnostic but not prognostic or predictive biomarker.
[81] Bekes et al. 2019 Ovarian cancer 60 CD112 expression supported tumor cell adhesion, leading to growth and lymph node metastasis.
  1. aSC/ASC: squamous cell/adenosquamous carcinoma
  2. b AC: adenocarcinomas
  3. cincluding 139 AML patients enrolled in the AMLSG 07–04 study of the German-Austrian Study Group (NCT00151242) [78] and 290 AML patients in the GEO database (GEO accession GSE6891) [79]